Tag Archives: professor

Palbociclib shows promise in patients with hormone-resistant breast cancer

“The FDA approval has expanded treatments options for many metastatic breast cancer patients, but these new results are showing how effective the drug can also be for breast cancer patients who have already tried endocrine therapies and may be running out of options,” said lead investigator Angela DeMichele, MD, MSCE, associate professor in the division of Hematology/Oncology and Epidemiology and co-leader of the Breast Cancer Research Program at the Abramson Cancer Center. “Combined with the promising results from other trials looking at the effectiveness of this drug, our results indicate that palbociclib can extend the duration of disease control and produce tumor shrinkage in patients with estrogen-receptor positive (ER+) breast cancer, without the debilitating side effects of chemotherapy.” The newly-published phase II trial primarily sought to evaluate disease response and control, while monitoring for the presence of side effects such as neutropenia, an abnormally low white blood cell count. Patients enrolled in the trial had previously undergone several prior chemotherapy and hormonal regimens for metastatic disease…

New study reveals how to improve chemotherapy use in prostate cancer

“It was surprising to find that cabazitaxel functions differently than docetaxel in killing cancer cells, even though they’re both taxanes,” says senior author Karen Knudsen, Ph.D., Interim Director of the Sidney Kimmel Cancer Center and a professor of cancer biology at the Sidney Kimmel Medical College at Thomas Jefferson University. “It shows that we may not be taking full advantage of this next generation taxane in the clinic.” For years, docetaxel has been the only effective chemotherapy for men whose cancer was no longer responding to hormone treatments…

Cancer experience presents time for lifestyle changes in both survivors and family members

“A window of opportunity exists during the post-treatment transition period for oncology clinicians to reach out to patients and their caregivers who want to have a healthy start on life after cancer,” said Susan Mazanec, PhD, RN, AOCN, assistant professor at Case Western Reserve’s Frances Payne Bolton School of Nursing. Mazanec, also a nurse scientist at University Hospitals Case Medical Center’s Seidman Cancer Center, was lead investigator of the study, “Health Behaviors in Family Members of Patients Completing Cancer Treatment,” recently reported in Oncology Nursing Forum. Mazanec and colleagues surveyed and interviewed 50 patients diagnosed with breast, colorectal, head and neck, lung or prostate cancers and 38 caregivers within three week of a patient’s last treatment. The questions were designed to gauge family members’ intention, perceived benefit and confidence about eating a healthy diet, physical activity and smoking cessation…

Origins of colorectal cancer tumor cells traced

The scientists employed a “Big Bang” model of human colorectal cancer growth similar to the theory that the universe started from a single point and exploded outward. The team was led by Keck faculty researchers Darryl Shibata, M.D., professor of pathology, Keck School of Medicine of USC and Christina Curtis, Ph.D., M.Sc., assistant professor of medicine and genetics at Stanford University and adjunct assistant professor, department of Preventive Medicine, Keck School of Medicine of USC. “It’s like going back in time,” said Shibata. …

Epigenetic breakthrough: A first of its kind tool to study the histone code

This work, published in the journal Developmental Cell, opens the door to experiments that are expected to uncover new biology important for a host of conditions, such as neurological diseases, diabetes, obesity, and especially cancer, which has become a hotbed of epigenetic research. “People think cancer is a disease of uncontrolled proliferation, but that’s just one aspect of it,” said Robert Duronio, PhD, professor of biology and genetics and co-senior author. “Cancer is actually a disease of development in which the cells don’t maintain their proper functions; they don’t do what they’re supposed to be doing.” Somehow, the gene regulation responsible for proper cell development goes awry. …

New nanoparticle gene therapy strategy effectively treats deadly brain cancer in rats

Previous research on mice found that nanoparticles carrying genes can be taken up by brain cancer cells, and the genes can then be turned on. However, this is the first time these biodegradable nanoparticles have effectively killed brain cancer cells and extended survival in animals. For their studies, the Johns Hopkins team designed and tested a variety of nanoparticles made from different polymers, or plastics. When they found a good candidate that could deliver genes to rat brain cancer cells, they filled the nanoparticles with DNA encoding an enzyme, herpes simplex virus type 1 thymidine kinase (HSVtk), which turns a compound with little effect into a potent therapy that kills brain cancer cells. …

An extra protein gives naked mole rats more power to stop cancer

The protein is associated with a cluster of genes (called a locus) that is also found in humans and mice. It’s the job of that locus to encode–or carry the genetic instructions for synthesizing –several cancer-fighting proteins. As Professor of Biology Vera Gorbunova explains, the locus found in naked mole rats encodes a total of four cancer-fighting proteins, while the human and mouse version encodes only three proteins. …

Parkinson’s gene linked to lung cancer

The findings are published in American Journal of Human Genetics. Through whole exome sequencing, researchers identified a link between a mutation in PARK2, a gene associated with early-onset Parkinson’s disease, and familial lung cancer. The researchers sequenced the exomes (protein coding region of the genome) of individuals from a family with multiple cases of lung cancer. They then studied the PARK2 gene in additional families affected by lung cancer…